On May 18, 2015 OPKO Health, Inc. (NYSE:OPK) reported six important new clinical trial results pertaining to the 4Kscore test presented at the 2015 American Urological Association (AUA) annual meeting, May 15 to May 19, 2015, in New Orleans (Press release, Opko Health, MAY 18, 2015, View Source [SID:1234506562]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Date and time, title and location of the 4Kscore presentations at the New Orleans Morial Convention Center (NOMCC):
Friday, May 15, 1:00 pm – Moderated poster MP6-04: The 4Kscore Test predicts high-grade prostate cancer on biopsy with PSA less than 4 ng/mL; NOMCC #220-221
Sunday May 17, 11:10 am – Urologic Oncology Forum podium presentation: Screening for lethal prostate cancer using PSA and related blood biomarkers; NOMCC #356-357
Sunday May 17, 12:50 am – Urologic Oncology Forum podium presentation: Use of commercial blood biomarkers to identify risk of aggressive prostate cancer; NOMCC #356-357
Monday, May 18, 8:00 am – Moderated poster MP60-06: The performance of the 4Kscore for predicting high-grade cancer on biopsy of the prostate does not depend on the age of the patient; NOMCC #206-207
Monday May 18, 10:30 am – Podium presentation PD38-03: The 4Kscore is associated with more advanced disease at radical prostatectomy; Results from a multi-Institutional prospective trial; NOMCC #215-216
Tuesday, May 19, 8:00 am – Moderated poster MP77-20: Among men with low-grade prostate cancer on prostate biopsy, the 4Kscore predicts more aggressive prostate cancer at prostatectomy; NOMCC 228-230
In addition to the regular AUA program presentations, the OPKO 4Kscore test will also be featured on Tuesday May 19th in an industry program titled "Biomarkers and Genomic Testing in Prostate Cancer: Integration Into Clinical Practice" from 10:00 – 11:00 am at NOMCC Science and Technology Hall #1043
About the 4Kscore Test
The 4Kscore is the only blood test that accurately identifies risk for aggressive prostate cancer. The 4Kscore measures the blood levels of four different prostate-derived kallikrein proteins: Total PSA, Free PSA, Intact PSA and Human Kallikrein-2 (hK2). These biomarkers are combined with a patient’s age, Digital Rectal Exam (DRE) status (nodule / no nodule), and prior negative biopsy status (yes / no) using a proprietary algorithm to calculate the risk (probability) of finding a Gleason Score 7 or higher prostate cancer. The four kallikrein panel of biomarkers utilized in the 4Kscore Test is based on over a decade of research conducted by scientists at Memorial Sloan-Kettering Cancer Center and leading European institutions. The 4Kscore Test provides individualized risk for the presence of aggressive prostate cancer and adds new information to the shared decision making discussion between a Urologist and patient.